Nanomedicine for the reduction of the thrombogenicity of stent coatings.
The treatment of patients with drug-eluting stents (DES) continues to evolve with the current emergence of DES technology that offers a combination of pharmacological and mechanical approaches to prevent arterial restenosis. However, despite the promising short-term and mid-term outcomes of DES, there are valid concerns about adverse clinical effects of late stent thrombosis. In this study, we present an example of how nanomedicine can offer solutions for improving stent coating manufacturing, by producing nanomaterials with tailored and controllable properties. The study is based on the exploitation of human platelets response towards carbon-based nanocoatings via atomic force microscope (AFM). AFM can facilitate the comprehensive analysis of platelets behavior onto stent nanocoatings and enable the study of thrombogenicity. Platelet-rich plasma from healthy donors was used for the real-time study of biointerfacial interactions. The carbon nanomaterials were developed by rf magnetron sputtering technique under controllable deposition conditions to provide favorable surface nanotopography. It was shown that by altering the surface topography of nanocoatings, the activation of platelets can be affected, while the carbon nanocoatings having higher surface roughness were found to be less thrombogenic in terms of platelets adhesion. This is an actual solution for improving the stent coating fabrication.
Karagkiozaki
Varvara C
VC
Aristotle University of Thessaloniki, Medical School, AHEPA University General Hospital, 1st Cardiology Department, Cardiovascular Engineering and Atherosclerosis Laboratory, Greece.
Logothetidis
Stergios D
SD
Kassavetis
Spyridon N
SN
Giannoglou
George D
GD
D001792:Blood Platelets / Q000187:drug effects*; D002244:Carbon / Q000008:administration & dosage* / Q000737:chemistry; D002478:Cells, Cultured; D020099:Coated Materials, Biocompatible / Q000009:adverse effects* / Q000627:therapeutic use*; D006801:Humans; D008422:Materials Testing; D050997:Nanomedicine / Q000379:methods; D053758:Nanoparticles / Q000008:administration & dosage* / Q000737:chemistry; D015539:Platelet Activation / Q000187:drug effects*; D015607:Stents / Q000009:adverse effects*; D013927:Thrombosis / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*
D020099:Coated Materials, Biocompatible; D002244:Carbon
Int J Nanomedicine. 2008;3(4):461-9
19337414
JAMA. 2005 Sep 14;294(10):1215-23
16160130
JAMA. 2005 May 4;293(17):2126-30
15870416
Nanomedicine. 2009 Mar;5(1):64-72
18848813
Science. 1992 Sep 25;257(5078):1900-5
1411505
Curr Top Med Chem. 2008;8(4):270-80
18393890
N Engl J Med. 2007 Mar 8;356(10):998-1008
17296824
J Microsc. 1998 Jun;190(Pt 3):328-38
9674158
Biomol Eng. 2007 Feb;24(1):119-24
16891153
Biophys J. 1994 May;66(5):1328-34
8061188
J Biomed Mater Res A. 2005 Jun 15;73(4):476-84
15880725
Biomaterials. 2007 Jan;28(2):354-69
21898921
J Am Coll Cardiol. 2007 Jul 10;50(2):119-27
17616295
JAMA. 2008 Jan 30;299(4):454-5
18230785
Colloids Surf B Biointerfaces. 2006 Jan 15;47(1):85-9
16406494
Biomaterials. 2007 Oct;28(28):4033-8
17576006
J Vasc Surg. 2006 Dec;44(6):1363-8
17145446
Acta Biomater. 2009 Jan;5(1):249-56
18753025
J Am Coll Cardiol. 2006 Jul 4;48(1):193-202
16814667
J Am Coll Cardiol. 2007 Jul 10;50(2):128-37
17616296
Biomaterials. 2003 Aug;24(17):2821-9
12742720
J Interv Cardiol. 2006 Dec;19(6):493-9
17107363
Lancet. 2007 Feb 24;369(9562):667-78
17321312
J Am Coll Cardiol. 2006 Jan 3;47(1):175-81
16386683
J Am Coll Cardiol. 2006 Apr 4;47(7):1356-60
16580521
Biomaterials. 2004 Jan;25(1):53-61
14580908
J Am Coll Cardiol. 2006 Feb 7;47(3):507-14
16458128